ELCC 2022 | Challenges in regards to adverse events when treating lung cancer with IO

Michel Obeid, MD, PhD, CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, talks on remaining challenges in regards to adverse events (AEs) when treating lung cancer with immunotherapy, including understanding the pathogenesis of AEs and finding an appropriate balance between maintaining an oncological response and risk of severe toxicity. This interview took place during the virtual European Lung Cancer Congress 2022.